Symbols / NRXP Stock $2.94 +3.52% NRx Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
NRXP (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Jonathan C. Javitt M.D., M.P.H.
Exch · Country NCM · United States
Market Cap 97.22M
Enterprise Value 89.96M
Income -28.62M
Sales 1.23M
FCF (ttm) -805.88K
Book/sh -0.50
Cash/sh 0.24
Employees 29
Insider 10d —
IPO Dec 04, 2017
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E 5.88
PEG —
P/S 79.36
P/B -5.84
P/C —
EV/EBITDA -5.58
EV/Sales 73.43
Quick Ratio 0.28
Current Ratio 0.31
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -1.34
EPS next Y 0.50
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-15
Earnings (prior) 2026-03-23
ROA -121.85%
ROE —
ROIC —
Gross Margin 58.78%
Oper. Margin -4.67%
Profit Margin 0.00%
Shs Outstand 33.07M
Shs Float 24.24M
Insider Own 8.30%
Instit Own 25.16%
Short Float 10.38%
Short Ratio 3.57
Short Interest 3.25M
52W High 3.84
vs 52W High -23.44%
52W Low 1.62
vs 52W Low 81.48%
Beta 1.83
Impl. Vol. 12.50%
Rel Volume 0.58
Avg Volume 811.75K
Volume 473.45K
Target (mean) $38.00
Tgt Median $39.50
Tgt Low $25.00
Tgt High $48.00
# Analysts 4
Recom Strong_buy
Prev Close $2.84
Price $2.94
Change 3.52%
About

NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$38.00
Mean price target
2. Current target
$2.94
Latest analyst target
3. DCF / Fair value
$-0.44
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.94
Low
$25.00
High
$48.00
Mean
$38.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-23 main D. Boral Capital Buy → Buy $34
2026-04-20 main D. Boral Capital Buy → Buy $34
2026-03-24 main D. Boral Capital Buy → Buy $34
2026-03-24 reit BTIG Buy → Buy $25
2026-03-17 main D. Boral Capital Buy → Buy $34
2026-03-16 main D. Boral Capital Buy → Buy $34
2026-03-09 main D. Boral Capital Buy → Buy $34
2026-03-03 main HC Wainwright & Co. Buy → Buy $45
2026-02-18 reit BTIG Buy → Buy $25
2026-02-17 main D. Boral Capital Buy → Buy $34
2026-01-15 reit BTIG Buy → Buy $25
2026-01-05 main D. Boral Capital Buy → Buy $34
2026-01-02 main Ascendiant Capital Buy → Buy $48
2025-12-16 reit HC Wainwright & Co. Buy → Buy $40
2025-12-03 main D. Boral Capital Buy → Buy $34
2025-12-03 reit BTIG Buy → Buy $25
2025-12-02 main D. Boral Capital Buy → Buy $34
2025-11-17 main D. Boral Capital Buy → Buy $34
2025-11-10 main D. Boral Capital Buy → Buy $34
2025-10-30 main Ascendiant Capital Buy → Buy $47
News
RSS: Latest NRXP news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2024-12-17 JAVITT JONATHAN C Chairman of the Board — 40,000 $1.64 $65,600
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
1.23
0.00
0.00
0.00
Operating Revenue
1.23
0.00
0.00
0.00
Cost Of Revenue
0.51
0.00
—
—
Reconciled Cost Of Revenue
0.43
0.00
—
—
Gross Profit
0.72
0.00
—
—
Operating Expense
16.94
-8.42%
18.50
-32.93%
27.59
-37.78%
44.34
Research And Development
3.78
-39.07%
6.20
-53.64%
13.37
-21.47%
17.03
Selling General And Administration
13.06
-3.25%
13.50
-5.04%
14.22
-47.94%
27.31
General And Administrative Expense
13.06
-3.25%
13.50
-5.04%
14.22
-47.94%
27.31
Other Gand A
13.06
-3.25%
13.50
-5.04%
14.22
-47.94%
27.31
Other Operating Expenses
0.04
+103.00%
-1.20
-580.80%
0.25
—
Total Expenses
17.45
-5.69%
18.50
-32.93%
27.59
-37.78%
44.34
Operating Income
-16.22
+12.31%
-18.50
+32.93%
-27.59
+37.78%
-44.34
Total Operating Income As Reported
-16.22
+12.31%
-18.50
+33.53%
-27.84
+37.21%
-44.34
EBITDA
-27.81
-11.72%
-24.89
+17.10%
-30.02
+24.47%
-39.75
Normalized EBITDA
-26.97
-16.10%
-23.23
+22.02%
-29.80
+33.18%
-44.59
Reconciled Depreciation
0.14
+2760.00%
0.01
+0.00%
0.01
+25.00%
0.00
EBIT
-27.95
-12.27%
-24.90
+17.10%
-30.03
+24.46%
-39.75
Total Unusual Items
-0.83
+49.67%
-1.66
-620.43%
-0.23
-104.76%
4.84
Total Unusual Items Excluding Goodwill
-0.83
+49.67%
-1.66
-620.43%
-0.23
-104.76%
4.84
Special Income Charges
—
—
-0.25
-105.46%
4.58
Other Special Charges
—
—
0.25
—
Restructuring And Mergern Acquisition
—
—
0.00
+100.00%
-4.58
Net Income
-28.62
-13.91%
-25.13
+16.66%
-30.15
+24.16%
-39.75
Pretax Income
-28.62
-13.91%
-25.13
+16.66%
-30.15
+24.16%
-39.75
Net Non Operating Interest Income Expense
-0.66
-254.30%
-0.19
-149.73%
0.37
+50.20%
0.25
Interest Expense Non Operating
0.67
+191.74%
0.23
+91.67%
0.12
0.00
Net Interest Income
-0.66
-254.30%
-0.19
-149.73%
0.37
+50.20%
0.25
Interest Expense
0.67
+191.74%
0.23
+91.67%
0.12
0.00
Interest Income Non Operating
0.01
-72.73%
0.04
-91.09%
0.49
+98.39%
0.25
Interest Income
0.01
-72.73%
0.04
-91.09%
0.49
+98.39%
0.25
Other Income Expense
-11.74
-82.34%
-6.44
-119.20%
-2.94
-167.80%
4.33
Other Non Operating Income Expenses
-10.87
-127.36%
-4.78
-76.62%
-2.71
-436.04%
-0.51
Gain On Sale Of Security
-0.83
+49.67%
-1.66
-8385.00%
0.02
-92.16%
0.26
Tax Provision
—
—
—
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-28.62
-13.91%
-25.13
+16.66%
-30.15
+24.16%
-39.75
Net Income From Continuing Operation Net Minority Interest
-28.62
-13.91%
-25.13
+16.66%
-30.15
+24.16%
-39.75
Net Income From Continuing And Discontinued Operation
-28.62
-13.91%
-25.13
+16.66%
-30.15
+24.16%
-39.75
Net Income Continuous Operations
-28.62
-13.91%
-25.13
+16.66%
-30.15
+24.16%
-39.75
Normalized Income
-27.79
-18.40%
-23.47
+21.56%
-29.92
+32.90%
-44.59
Net Income Common Stockholders
-28.62
-13.91%
-25.13
+16.69%
-30.16
+24.14%
-39.75
Otherunder Preferred Stock Dividend
—
0.00
-100.00%
0.01
0.00
Diluted EPS
—
-2.36
+40.70%
-3.98
+34.75%
-6.10
Basic EPS
—
-2.36
+40.70%
-3.98
+34.75%
-6.10
Basic Average Shares
—
10.64
+40.50%
7.58
+15.20%
6.58
Diluted Average Shares
—
10.64
+40.50%
7.58
+15.20%
6.58
Diluted NI Availto Com Stockholders
-28.62
-13.91%
-25.13
+16.69%
-30.16
+24.14%
-39.75
Depreciation Amortization Depletion Income Statement
0.07
+1300.00%
0.01
—
—
Depreciation And Amortization In Income Statement
0.07
+1300.00%
0.01
—
—
Earnings From Equity Interest
-0.04
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
12.96
+254.86%
3.65
-50.09%
7.32
-71.66%
25.82
Current Assets
8.89
+169.29%
3.30
-52.03%
6.88
-73.31%
25.80
Cash Cash Equivalents And Short Term Investments
7.80
+440.33%
1.44
-68.60%
4.59
-77.09%
20.05
Cash And Cash Equivalents
7.80
+440.33%
1.44
-68.60%
4.59
-77.09%
20.05
Cash Financial
—
—
—
20.05
Receivables
0.16
0.00
-100.00%
0.01
-14.29%
0.01
Accounts Receivable
0.16
0.00
—
—
Other Receivables
—
—
0.01
-14.29%
0.01
Prepaid Assets
0.93
-49.76%
1.86
-18.57%
2.28
-60.18%
5.73
Total Non Current Assets
4.06
+1064.47%
0.35
-19.03%
0.43
+1952.38%
0.02
Net PPE
0.70
+6860.00%
0.01
—
—
Gross PPE
0.70
+6860.00%
0.01
—
—
Other Properties
0.70
+6860.00%
0.01
—
—
Goodwill And Other Intangible Assets
2.72
0.00
—
—
Goodwill
1.79
0.00
—
—
Other Intangible Assets
0.93
—
—
—
Investments And Advances
0.40
0.00
—
—
Long Term Equity Investment
0.40
0.00
—
—
Other Non Current Assets
0.25
-25.37%
0.34
-21.35%
0.43
+1952.38%
0.02
Total Liabilities Net Minority Interest
28.89
+7.51%
26.87
+41.09%
19.05
+3.48%
18.41
Current Liabilities
28.58
+30.71%
21.86
+14.78%
19.05
+22.22%
15.59
Payables And Accrued Expenses
9.95
+6.27%
9.37
+3.66%
9.04
+15.17%
7.84
Payables
4.27
+3.39%
4.13
-10.84%
4.63
+123.12%
2.08
Accounts Payable
4.27
+3.39%
4.13
-10.84%
4.63
+123.12%
2.08
Current Accrued Expenses
5.68
+8.54%
5.24
+18.92%
4.40
-23.68%
5.77
Pensionand Other Post Retirement Benefit Plans Current
0.50
-14.04%
0.58
-30.90%
0.83
—
Current Debt And Capital Lease Obligation
0.32
-79.82%
1.57
-82.91%
9.16
+18.93%
7.70
Current Debt
—
1.57
-82.91%
9.16
+18.93%
7.70
Other Current Borrowings
—
1.57
-82.91%
9.16
+18.93%
7.70
Current Capital Lease Obligation
0.32
0.00
—
—
Other Current Liabilities
12.30
+118.19%
5.64
+33070.59%
0.02
-54.05%
0.04
Total Non Current Liabilities Net Minority Interest
0.32
-93.71%
5.01
0.00
-100.00%
2.82
Long Term Debt And Capital Lease Obligation
0.32
-93.71%
5.01
—
2.82
Long Term Debt
—
5.01
—
2.82
Long Term Capital Lease Obligation
0.32
0.00
—
—
Stockholders Equity
-15.94
+31.37%
-23.22
-97.93%
-11.73
-258.36%
7.41
Common Stock Equity
-15.94
+31.37%
-23.22
-97.88%
-11.74
-258.40%
7.41
Capital Stock
0.03
+113.33%
0.01
+36.36%
0.01
-83.58%
0.07
Common Stock
0.03
+113.33%
0.01
+87.50%
0.01
-88.06%
0.07
Preferred Stock
0.00
0.00
-100.00%
0.00
0.00
Share Issued
31.73
+117.48%
14.59
+73.87%
8.39
+26.30%
6.64
Ordinary Shares Number
31.73
+117.48%
14.59
+73.87%
8.39
+26.30%
6.64
Additional Paid In Capital
290.93
+14.07%
255.03
+5.65%
241.41
+4.80%
230.34
Retained Earnings
-306.89
-10.29%
-278.27
-9.93%
-253.15
-13.52%
-223.00
Gains Losses Not Affecting Retained Earnings
—
0.00
+100.00%
-0.00
0.00
Other Equity Adjustments
—
—
-0.00
—
Total Equity Gross Minority Interest
-15.94
+31.37%
-23.22
-97.93%
-11.73
-258.36%
7.41
Total Capitalization
-15.94
+12.49%
-18.21
-55.22%
-11.73
-214.68%
10.23
Working Capital
-19.69
-6.06%
-18.56
-52.59%
-12.16
-219.14%
10.21
Invested Capital
-15.94
+4.26%
-16.65
-546.45%
-2.58
-114.36%
17.93
Total Debt
0.63
-90.41%
6.58
-28.21%
9.16
-12.96%
10.53
Net Debt
—
5.13
+12.44%
4.57
—
Capital Lease Obligations
0.63
0.00
—
—
Net Tangible Assets
-18.66
+19.67%
-23.22
-97.93%
-11.73
-258.36%
7.41
Tangible Book Value
-18.66
+19.67%
-23.22
-97.88%
-11.74
-258.40%
7.41
Current Notes Payable
—
—
—
0.00
Current Provisions
5.51
+16.84%
4.71
—
—
Preferred Stock Equity
—
—
0.00
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-14.11
-32.67%
-10.64
+50.88%
-21.66
+45.52%
-39.76
Cash Flow From Continuing Operating Activities
-14.11
-32.67%
-10.64
+50.88%
-21.66
+45.52%
-39.76
Net Income From Continuing Operations
-28.62
-13.91%
-25.13
+16.66%
-30.15
+24.16%
-39.75
Depreciation Amortization Depletion
0.14
+2760.00%
0.01
+0.00%
0.01
+25.00%
0.00
Depreciation
0.14
+2760.00%
0.01
+0.00%
0.01
+25.00%
0.00
Depreciation And Amortization
0.14
+2760.00%
0.01
+0.00%
0.01
+25.00%
0.00
Other Non Cash Items
5.62
-2.63%
5.77
+95.20%
2.96
+172.53%
-4.08
Stock Based Compensation
0.23
-53.09%
0.49
+25.58%
0.39
-89.33%
3.63
Provisionand Write Offof Assets
0.04
0.00
—
—
Operating Gains Losses
7.07
+140.89%
2.94
+14775.00%
-0.02
+92.16%
-0.26
Gain Loss On Investment Securities
-0.44
-126.74%
1.66
+8385.00%
-0.02
+92.16%
-0.26
Change In Working Capital
1.41
-73.37%
5.29
+2.46%
5.16
+638.77%
0.70
Change In Receivables
0.05
0.00
—
0.00
Changes In Account Receivables
0.05
0.00
—
0.00
Change In Prepaid Assets
0.86
+71.97%
0.50
-83.45%
3.04
+581.01%
-0.63
Change In Payables And Accrued Expense
0.61
-87.18%
4.79
+125.42%
2.12
+59.58%
1.33
Change In Accrued Expense
0.50
-94.99%
10.01
+1984.18%
-0.53
-118.05%
2.94
Change In Payable
0.11
+102.17%
-5.22
-296.50%
2.65
+264.80%
-1.61
Change In Account Payable
0.11
+102.17%
-5.22
-296.50%
2.65
+264.80%
-1.61
Change In Other Current Liabilities
-0.12
0.00
—
—
Investing Cash Flow
-2.81
0.00
+100.00%
-0.00
+70.00%
-0.01
Cash Flow From Continuing Investing Activities
-2.81
0.00
+100.00%
-0.00
+70.00%
-0.01
Net PPE Purchase And Sale
—
0.00
+100.00%
-0.00
+70.00%
-0.01
Purchase Of PPE
—
0.00
+100.00%
-0.00
+70.00%
-0.01
Capital Expenditure
—
—
-0.00
+70.00%
-0.01
Net Investment Purchase And Sale
-0.43
0.00
—
—
Purchase Of Investment
-0.43
0.00
—
—
Net Business Purchase And Sale
-2.38
0.00
—
—
Purchase Of Business
-2.38
0.00
—
—
Financing Cash Flow
23.28
+210.97%
7.49
+20.71%
6.20
-80.75%
32.21
Cash Flow From Continuing Financing Activities
23.28
+210.97%
7.49
+20.71%
6.20
-80.75%
32.21
Net Issuance Payments Of Debt
4.68
+412.77%
-1.50
+51.62%
-3.09
-132.54%
9.50
Issuance Of Debt
5.23
-26.16%
7.08
+650.69%
0.94
-90.59%
10.02
Repayment Of Debt
-0.55
+93.61%
-8.57
-112.52%
-4.04
-678.96%
-0.52
Long Term Debt Issuance
5.23
-26.16%
7.08
+650.69%
0.94
-90.59%
10.02
Long Term Debt Payments
-0.55
+93.61%
-8.57
-112.52%
-4.04
-678.96%
-0.52
Net Long Term Debt Issuance
4.68
+412.77%
-1.50
+51.62%
-3.09
-132.54%
9.50
Short Term Debt Payments
—
—
—
-0.52
Net Short Term Debt Issuance
—
—
—
-0.52
Net Common Stock Issuance
15.86
+168.31%
5.91
-27.22%
8.12
-64.22%
22.70
Proceeds From Stock Option Exercised
3.09
-22.16%
3.97
0.00
-100.00%
0.01
Net Other Financing Charges
-0.35
+60.94%
-0.90
—
—
Changes In Cash
6.35
+301.59%
-3.15
+79.61%
-15.46
-104.73%
-7.55
Beginning Cash Position
1.44
-68.60%
4.59
-77.09%
20.05
-27.35%
27.61
End Cash Position
7.80
+440.33%
1.44
-68.60%
4.59
-77.09%
20.05
Free Cash Flow
-14.11
-32.67%
-10.64
+50.89%
-21.66
+45.53%
-39.77
Interest Paid Supplemental Data
0.00
-100.00%
0.37
-57.74%
0.89
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Common Stock Issuance
15.86
+168.31%
5.91
-27.22%
8.12
-64.22%
22.70
Earnings Losses From Equity Investments
0.04
0.00
—
—
Issuance Of Capital Stock
15.86
+168.31%
5.91
-36.39%
9.29
-59.07%
22.70
Net Preferred Stock Issuance
—
0.00
-100.00%
1.17
0.00
Preferred Stock Issuance
—
0.00
-100.00%
1.17
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category